Hepatocellular carcinoma (HCC) is the sixth most commonly diagnosed cancer and the fourth leading cause of death worldwide.1 Until recently, treatment options for advanced disease have been limited. Sorafenib—a tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor (VEGFR), platelet-derived growth factor, and RAF—was initially approved in 2008,2 and this drug had been the only first-line option for systemic therapy of advanced disease until the noninferiority of lenvatinib, a VEGFR/RET/fibroblast growth factor receptor TKI, was demonstrated a decade later.